NCT04315116已完成1 期
A Single Center, Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Loperamide on Pyrotinib Maleate in Healthy Subjects
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Pharmacokinetics parameter: AUC of pyrotinib
研究概览
简要总结
The primary objective of the study was to assess the effect of repeated oral doses of Loperamide on the pharmacokinetic profile of a single dose of Pyrotinib Maleate.
The secondary objective of the study was to assess the safety of Pyrotinib Maleate given alone versus Fluzoparib coadministered with Loperamide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent form before the trial and fully understand the trial content, process and possible adverse reactions; 2) Ability to complete the study as required by the protocol; 3) Age on the date of signing the informed consent form is 18 to 45 years old (including both ends); 4) The fasting weight is not less than 50kg (male) and 45kg (female), and the body mass index (BMI) is in the range of 19 kg/m2 to 26 kg/m2 (including both ends);
排除标准
- •Participate in blood donation within 3 months before screening and donate blood volume ≥400mL or blood loss ≥400mL, or receive blood transfusion; 2) Allergic constitution, including a history of severe drug allergy or drug allergy; a history of allergies to Pyrotinib/ Loperamide capsule or its excipients; 3) with drug and/or alcohol abuse history, or alcohol and drug screening positives, or drug abuse in the past five years or used drugs 3 months before the trial; 4) Patients with bad habits (such as drinking 14 units of alcohol per week: 1 unit = 285mL of beer, 25mL of spirits, or 100mL of wine), smoking addiction (≥5 cigarettes per day);and could not prohibit smoking and alcohol during the trial period ; 5) QTc interval ≥ 450 ms in males and ≥ 470 ms in females; 6) left ventricular ejection fraction (LVEF) < 50% by echocardiography; 7) Other important organ diseases such as the nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolic and musculoskeletal system with clear medical history (such as uncontrolled diabetes, high blood pressure, etc.), enabling investigators considered unsuitable for participation in the study; 8) Anyone who has undergone any surgery within the first 6 months of screening; 9) Take any hepatotoxic drugs (eg dapsone, erythromycin, fluconazole, ketoconazole, rifampicin, etc.) within the first 6 months of screening; 10) Those who have taken any clinical trial drugs within 3 months; 11) Take any drug that affects liver metabolism within 4 weeks before taking the investigational drug; 12) Take any prescription or over-the-counter medication, vitamin products or herbs within 2 weeks before taking the investigational drug; 13) Clinical laboratory tests are abnormal and clinically significant, or other clinical findings indicate the following diseases, including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular disease; 14) Female subjects during pregnancy, lactation, and subjects who were unable to abstain or take effective non-drug contraceptives during the study period and for at least 3 months after the last study drug administration (for female subjects Require abstinence or effective non-drug contraceptives two weeks before study entry); 15) combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection; 16) Anyone who has ingested grapefruit or grapefruit-containing products, foods or drinks containing caffeine, xanthine or alcohol; strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion Within 48 hours; 17) Anyone who has pseudoulcerative colitis caused by acute ulcerative colitis or broad-spectrum antibiotics, or those who need to avoid inhibition of bowel movements, especially patients with intestinal obstruction, flatulence or constipation, or have diarrhea, dry mouth, Gastrointestinal symptoms such as bloating, loss of appetite, gastrointestinal cramps, nausea, vomiting, constipation, and dizziness, headache, and fatigue; 18) Anyone who has special requirements for diet and cannot comply with the diet and corresponding regulations provided by the test; 19) Anyone who has a history of dizzy needles and blood halo, who have difficulty collecting blood or cannot tolerate venipuncture; 20) The investigator believes that the subjects are not eligible to participate in this trial.
研究组 & 干预措施
Treament
Experimental
Subjects receiving a single oral dose of pyrotinib maleate and wash-out for 6 days, then receiving Loperamide 4 mg bid from day 7 to day 13, with a single oral dose of pyrotinib maleate coadministered on day 10 .
干预措施: pyrotinib maleate (Drug)
Treament
Experimental
Subjects receiving a single oral dose of pyrotinib maleate and wash-out for 6 days, then receiving Loperamide 4 mg bid from day 7 to day 13, with a single oral dose of pyrotinib maleate coadministered on day 10 .
干预措施: Loperamide (Drug)
结局指标
主要结局
Pharmacokinetics parameter: AUC of pyrotinib
时间窗: through study completion, an average of 20 days
Area under the plasma concentration versus time curve (AUC) of pyrotinib
Pharmacokinetics parameter: Cmax of pyrotinib
时间窗: through study completion, an average of 20 days
Peak Plasma Concentration (Cmax) of pyrotinib
次要结局
- Pharmacokinetics parameter: T1/2 of pyrotinib(through study completion, an average of 20 days)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(through study completion, an average of 20 days)
- Pharmacokinetics parameter: Tmax of pyrotinib(through study completion, an average of 20 days)
- Pharmacokinetics parameter: CL/F of pyrotinib(through study completion, an average of 20 days)
- Pharmacokinetics parameter: Vz/F of pyrotinib(through study completion, an average of 20 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on FluzoparibHealthy Male SubjectsNCT04011124Jiangsu HengRui Medicine Co., Ltd.16
已完成
1 期
A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on FamitinibHealthy Adult SubjectsNCT04494659Jiangsu HengRui Medicine Co., Ltd.21
已完成
3 期
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide TreatmentEpilepsyNCT04627285UCB Biopharma SRL48
已完成
1 期
A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy ParticipantsHeathy ParticipantsNCT04090047Pfizer12
已完成
1 期
The Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsInteractionNCT03498170Mereo BioPharma16